|Nom||Titre||Payer||Exercé||Année de naissance|
|Dr. Jeffrey Marc Leiden M.D., Ph.D.||Exec. Chairman||281,98k||S.O.||1956|
|Dr. Reshma Kewalramani FASN, M.D.||CEO, Pres & Director||4,27M||S.O.||1973|
|Mr. Charles F. Wagner Jr.||Exec. VP & CFO||1,85M||S.O.||1968|
|Mr. Stuart A. Arbuckle B.Sc.||Exec. VP & COO||2,56M||197,69k||1966|
|Dr. Ourania Tatsis Ph.D.||Exec. VP and Chief Regulatory & Quality Officer||1,33M||S.O.||1971|
|Ms. Kristen C. Ambrose||Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services||S.O.||S.O.||1977|
|Dr. David M. Altshuler M.D., Ph.D.||Exec. VP of Global Research & Chief Scientific Officer||S.O.||S.O.||1965|
|Mr. Mike Tirozzi||SVP and Chief Information & Data Officer||S.O.||S.O.||S.O.|
|Susie Lisa||Sr. VP of Investor Relations||S.O.||S.O.||S.O.|
|Mr. Damian W. Wilmot Esq.||Sr. VP, Chief Risk and Compliance Officer||S.O.||S.O.||1976|
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
L’ISS Governance QualityScore de Vertex Pharmaceuticals Incorporated en date du 1 janvier 2023 est 7. Les scores principaux sont Audit : 10; Société : 7; Droits des actionnaires : 6; Compensation : 6.